Introduction
============

Large artery stiffness is a principal determinant of pulse pressure and can increase the risk of cardiovascular morbidity and mortality via an elevation of systolic blood pressure (leading to elevations in left ventricular afterload) and a reduction in diastolic blood pressure altering coronary perfusion ([@b35]). Such stiffening can occur via processes that involve changes in the overall dimensions of arteries arising from medial hypertrophy and increased wall thickness -- "geometry-dependent" ([@b11]; [@b57]); or it can result from perturbations in the amounts of arterial matrix, both elastic and extracellular, such that the orderly arrangement of elastic fibers and lamenae is degraded over time and an increase in collagenous material occurs -- "geometry-independent" ([@b73]; [@b77]). Although a number of factors combine to determine increases in large artery stiffening, a principal determinant is age; the central arteries stiffen progressively over time while the peripheral muscular arteries do not appear to undergo such profound structural changes ([@b15]). Indeed, by use of a variety of assessment criteria, age-dependent increases in arterial stiffening have been described in both healthy and diseased populations, predominantly occurring from the age of 10 years in both males and females ([@b74]). These increases in large artery stiffness, whether they occur within the aorta or carotid artery, do so in a continuous and gradual manner ([@b124]), although there is some indication that a more pronounced increase occurs from the age of 55 years onwards ([@b92]). It is interesting that telomeric length, a heritable indicator of biological aging, may also be indicative of vascular aging given that it appears to inversely correlate with increased arterial stiffening ([@b58]; [@b14]).

Whereas large artery stiffening increases gradually with aging independently of the occurrence of cardiovascular risk factors or other associated conditions, a number of studies clearly suggest that the superimposition of environmental and genetic factors is also likely to be critical in the process. Some of these environmental factors include nutritional status, smoking, and aerobic capacity. Increasingly, the influence of genetic factors is becoming better understood in terms of how it may affect the epidemiology of large artery stiffening. Studies carried out a decade ago in rat models of salt-sensitive hypertension ([@b7]; [@b82]) and in human sodium-sensitive hypertensives ([@b32]) seem to indicate that hemodynamic and humoral factors alone cannot fully account for differences in mechanoelastic arterial properties when compared with the situation in salt-resistant or normotensive controls. This suggests a major influence of predisposing genetic factors on arterial mechanical properties. Indeed, some studies suggest that the total genetic heritability of aortic stiffening determinants, which are independent of the influence of blood pressure, heart rate, height, and age, may make a substantial contribution, perhaps as high as 30%--40% ([@b115]). Furthermore, the results of genome-wide linkage analyses of pulse pressure indicate that while some overlap may exist between genetic components that underlie blood pressure phenotypes ([@b4]), there is also likely to be a distinct set of genes that contribute to the modulation of arterial stiffness ([@b24]; [@b30]). In this regard, a number of polymorphisms in various genes have been found to associate with increased arterial stiffening, thereby implicating these genes in this process. In this review, the current knowledge about these genetic factors is discussed, as is the potential molecular basis that underlies their involvement in arterial stiffening, particularly as it relates to the growth of arteries, the structure and remodeling of the extracellular matrix, and the interactions that occur between the extracellular matrix and the cellular components of the artery.

Nonmatrix gene polymorphisms
============================

The renin--angiotensin system
-----------------------------

Local hormonal factors that may play a pressure-independent role in the arterial wall via a modification of cellular growth or by influencing the extracellular matrix include angiotensin II acting via the angiotensin II type 1 receptor (AT~1~-R). Animal studies using both Wistar Kyoto and spontaneously hypertensive rats (SHR) have demonstrated that inhibition of angiotensin-converting enzyme (ACE) activity can reduce stiffness within the carotid artery independently of transmural pressure, both when the drug was administered locally ([@b79]) and after acute oral administration ([@b13]). In both studies, changes in stiffness were seen even in the absence of significantly lowered systemic blood pressure. Experimentation using two-kidney, one-clip Goldblatt hypertensive rats, and SHR indicated that the beneficial effect of ACE inhibition may arise via effects on vascular smooth muscle cell hypertrophy ([@b80], [@b81]) or collagen accumulation ([@b1]; [@b12]).

While in humans the relationship between ACE inhibition and arterial stiffness is likely to be more complex, it has been demonstrated that long-term administration of ACE inhibitors to individuals with essential hypertension significantly reduces arterial stiffness within the brachial, radial, abdominal, and carotid arteries ([@b3]; [@b29]; [@b67]). Such findings are consistent with the observations of elevated levels of ACE in humans with increased thickness of the carotid wall ([@b20]). Both ACE inhibition and AT~1~-R blockade, in either acute or long-term treatment, can reduce the stiffness of muscular arteries independent of changes in mean blood pressure ([@b122], [@b121]; [@b9]). In view of these observations, it has been of interest to ascertain whether genetic polymorphism within the ACE and AT~1~-R genes may be associated with alterations in arterial stiffness. For example, it has been shown that specific polymorphisms within the AT~1~-R and ACE genes within hypertensive individuals do appear to be involved in the regulation of aortic stiffness. Specifically, in the study by [@b10], in which arterial stiffness was assessed by measuring aortic pulse wave velocity (PWV), the AT~1~-RA^1166^C polymorphism was the second most important determinant of aortic stiffness in hypertensives, accounting for 11.6% of PWV variance, an effect that appeared to be co-dominant. Although a strong association between the AT~1~-RA^1166^C genotype and PWV was observed in both young and old hypertensives, the effect was more pronounced in the older individuals, suggesting that this polymorphism may amplify the effects of age on arterial stiffness. Some studies have provided data consistent with the C allele influencing arterial stiffness, for example the demonstration that ACE inhibition with perindopril reduced PWV threefold in carriers of the C allele as compared with individuals homozygous for the A allele ([@b8]). Interestingly, the presence of the C allele has been associated with increased vasoconstriction of both the coronary arteries ([@b2]) and the internal mammary artery ([@b53]).

More evidence that the AT~1~-R A^1166^C polymorphism is likely to be a key determinant in the process of arterial stiffening has been provided in a recent study in which an additional cohort of individuals was also found to exhibit association between this polymorphism and arterial stiffening, although in this study ([@b41]) it was the A allele that was associated with such increased stiffening. Additional involvement of the AT~1~-R gene in the process of arterial stiffening has been provided by [@b72], demonstrating an age-related association between the AT~1~-R A^153^G polymorphism and aortic stiffness. In the study by [@b10], the ACE I/D polymorphism showed an association with aortic stiffness, albeit at a lower level, accounting for less than 2% of the PWV. This polymorphism has also been found to be associated with aortic and carotid artery stiffening in a group of 137 Japanese individuals with type 2 diabetes ([@b119]). In addition to these data is the study by [@b85], demonstrating an association between this polymorphism and common carotid artery stiffness in individuals younger than 70 years. Some studies also indicate that the ability of this polymorphism either to modulate increases in pulse pressure ([@b106]) or to influence diastolic blood pressure ([@b105]) is likely to be dependent on age and sex, with males being more susceptible to these outcomes. It should also be noted that there may be additional complexity to the relationship between the ACE I/D polymorphism and the AT~1~-R A^1166^C polymorphism and modulation of arterial stiffness, as there is evidence that in some population cohorts these polymorphisms do not strongly affect the stiffness of either the carotid or radial arteries ([@b44]).

A key factor that regulates the amount of angiotensin II is its generation from angiotensinogen. Polymorphisms have been detected within the human angiotensinogen gene, which appear to correlate with plasma concentrations of angiotensinogen, specifically the variant M235T, which arises from a thymidine-to-cytosine transition at nucleotide position 704 and causes substitution of a methionine for a threonine at residue 235 in the mature angiotensinogen peptide ([@b60]). In some studies the T235 allele has been found to be associated with higher plasma concentrations of angiotensinogen in individuals homozygous for this allele ([@b19]), and it has also been associated with hypertension ([@b26]). This polymorphism has also been found to associate with arterial structure, with hypertensive individuals homozygous for the T235 allele exhibiting a higher amount of carotid intimamedia thickness ([@b22]). More importantly, this polymorphism has also very recently been shown to be associated with arterial stiffness. In a study by [@b23] in which 98 untreated hypertensive individuals were assessed for arterial stiffness, those who were homozygous for the T235 allele had, on average, increased carotid artery stiffness compared with the T/M235 heterozygotes and the M235 homozygotes. Such data provide further evidence that perturbation within a number of the genes encoding for components of the renin--angiotensin system is likely to play a key role in the process of large artery stiffening.

Aldosterone synthase
--------------------

Aldosterone is a mineralocorticoid hormone which is involved in the regulation of blood pressure through its effects on sodium balance and intravascular volume ([@b125]). Experimental studies have demonstrated that aldosterone may be capable of playing a prominent role in regulating the structure of large arteries. For example, aldosterone receptors occur within the large arteries, particularly the aorta ([@b83]). Endogenous vascular synthesis of aldosterone can also occur ([@b118]). It has also been demonstrated that aldosterone can increase the expression of both cardiac and vascular collagens ([@b104]; [@b117]). It has been more recently demonstrated that aldosterone can amplify the proliferative effects of angiotensin II on vascular smooth muscle cells via an increase in expression of the AT~1~-R ([@b130]).

Synthesis of aldosterone occurs in the adrenal cortex from deoxycorticosterone, via the action of a mitochondrial cytochrome P450 enzyme aldosterone synthase (CYP11B2), the gene for which can be regulated by angiotensin II ([@b125]). Interestingly, polymorphisms within the CYP11B2 gene that may influence its activity have also been found. A common polymorphism within the promoter region has been demonstrated to influence binding of the transcriptional regulatory protein SF-1 ([@b126]). This C/T polymorphism (−344C/T), occurring 344 nucleotides upstream of the translational start site of the CYP11B2 protein, is within a region in which the steroidogenic transcription factor SF-1 binding occurs, and studies have found that plasma aldosterone levels or urinary aldosterone excretion can vary according to the −344 genotype ([@b51]; [@b100]). This polymorphism has also been found to be associated with arterial stiffening in a study in which 216 hypertensive individuals of European origin were assessed for plasma levels of renin and aldosterone, blood pressure, and PWV as a measure of arterial stiffness ([@b100]). The presence of the −344C allele was associated with elevated levels of plasma aldosterone, with the CC homozygous individuals having on average the highest levels, and the TT homozygotes having the lowest level. Individuals carrying the C allele also exhibited a higher degree of arterial stiffening as assessed from measurements of PWV. Consistent with such polymorphisms influencing arterial stiffness via perturbations in aldosterone levels have been the findings that an increase in carotid artery stiffness in response to long-term aldosterone administration to Sprague-Dawley rats can be ameliorated by treatment with the mineralocorticoid antagonist eplerenone ([@b70]) and that saltdependent increases in stiffness in the mesenteric vessels of spontaneously hypertensive stroke-prone rats could also be blunted by treatment with this aldosterone antagonist ([@b36]).

Moreover, there is evidence demonstrating that gene--gene interaction between components of the rennin--angiotensin--aldosterone system act to modulate large artery properties. For example, in a study of 756 Belgian individuals ranging in age from 12--79 years, a single-gene effect was observed to occur for the ACE I/D polymorphism on compliance of the common carotid artery, with the D allele being associated with decreased compliance ([@b5]). In multigenetic analysis, it was seen that the influence of the ACE D allele depended on both "vascular territory" and genetic background, such that the presence of the aldosterone −344T allele appeared necessary to bring about the negative association of the ACE D allele on distensibility of the common carotid artery ([@b5]). Although such an interaction occurred at the level of the common carotid artery, it did not appear to influence properties of the femoral artery. Rather, in the latter, ACE DD homozygotes, when additionally homozygous for the α-adducin Gly460 allele, had lower crosssectional compliance and lower distensibility ([@b5]).

Guanine nucleotide regulatory proteins (G-proteins)
---------------------------------------------------

G-proteins are key components of a plethora of intracellular signaling cascades, relaying signals from more than 1000 receptors to a diversity of intracellular effector molecules, including enzymes and ion channels ([@b38]). The structural features of the G-protein are an α-subunit bound loosely to a tightly associated dimer consisting of a β- and a γ-subunit, each subunit being the product of a different gene. Diversity of G-protein composition is generated via the number of different genes that encode for these subunits, with 16 α-subunit genes, 6 β-subunit genes, and 12 γ-subunit genes ([@b38]). It is known that mutations within these trimeric proteins are involved in a number of disease states, including hypertension. Specifically, a common C-to-T polymorphism in exon 10 (C825T) of the β3 subunit whereby the T allele is associated with a splice variant (GNB3-s) in which the nucleotides 498--620 of exon 9 are deleted in-frame, thereby truncating the β3 protein by 41 amino acids, has been demonstrated to be capable of significantly enhancing signaling when in a trimeric complex with Gα~i2~ and Gλ~5~ ([@b114]). Interestingly, the 825T allele has been associated with hypertension ([@b16]; [@b110]; [@b114]; [@b31]) and higher blood pressure ([@b16]; [@b110]; [@b52]). Moreover, the potential for this polymorphism to influence arterial structure has been demonstrated by the finding that in a French cohort of 306 individuals with no history of cardiovascular disease, a significant association existed between the 825T allele and radial artery hypertrophy, independent of age, blood pressure, sex, and body mass index ([@b49]). This polymorphism has been recently found to be associated with arterial stiffness, as measured by PWV and augmentation index ([@b95]). Specifically, this study compared a group of young healthy males with and without the 825T allele under resting conditions, finding that carriers of this allele exhibited a significantly higher PWV and augmentation index than individuals with the CC genotype. Although the underlying mechanistic basis linking such a polymorphism to arterial stiffening remains to be fully elucidated, it may relate to altered vascular remodeling events arising from aberrant vascular smooth muscle cell proliferation in response to enhanced Na^+^/H^+^ exchanger activity ([@b113]).

Nitric oxide synthase
---------------------

In addition to factors that can influence the growth of vascular smooth muscle cells or the expression of extracellular matrix proteins within the arterial wall, a degree of functional regulation of smooth muscle tone by circulating and locally produced vasoactive factors may also influence arterial stiffness. One such factor, nitric oxide, is synthesized from L-arginine in vascular endothelial cells by the action of the enzyme endothelial nitric oxide synthase (eNOS) and has a profound effect on both vascular tone and blood pressure ([@b97]; [@b103]). In this regard it has been demonstrated that both exogenous and endogenous eNOS inhibitors, which decrease basal endothelial cell eNOS, can cause an increase in carotid artery intimamedia thickness ([@b69]; [@b128]). Within the human eNOS gene, a polymorphic transversion of a G-to-T nucleotide at position 894 (G894T) within exon 7 results in a substitution of Glu by Asp at amino acid residue 298 (Glu298Asp) ([@b84]). This polymorphism has been shown to influence vascular responsiveness to vasoconstricting hormones, with the 894T allele being associated with an enhancement of the hemodynamic response to phenylephrine in a cohort of individuals undergoing cardiac pulmonary bypass surgery ([@b99]). Interestingly, a relationship between this polymorphism and blood pressure level was found to occur, with the T allele being associated with lower blood pressure in a young adult cohort aged 19--38 years in the Bogalusa Heart Study ([@b27]). In a recent study examining the independent effect of the G894T eNOS polymorphism on arterial stiffness in 118 African Americans and 285 white young adults (aged 25--37 years), the T allele was associated with lower systolic blood pressure and a lower degree of carotid artery stiffening within the African American cohort ([@b28]), after adjusting for insulin, heart rate, and mean arterial pressure. The genotype effect was not significant within the white male cohort, an observation consistent with a previous study utilizing a French cohort in which the T allele was not found to be significantly associated with PWV ([@b69]). It appears likely that the eNOS gene may be one of the key underlying factors that contribute to the observed ethnic differences in both hypertension and arterial stiffness. The mechanistic basis for how the G894T eNOS polymorphism could be linked with effects on arterial stiffness remains unclear, but is likely to relate to the ability of nitric oxide not only to be involved in the maintenance of vascular tone but also to exert an effect on arterial mechanical properties via inhibition of vascular smooth muscle cell proliferation ([@b42]; [@b59]). At this stage, the relationship between the G894T eNOS polymorphism and eNOS enzyme activity and subsequent nitric oxide production is yet to be clarified, with the polymorphism having no significant effect on eNOS activity in a study in which this parameter was tested ([@b63]). Another possibility is that the G894T polymorphism either is in strong linkage disequilibrium with another, as yet unidentified, eNOS polymorphism(s) that has an effect on enzyme activity or is linked with another gene that influences arterial stiffness.

Endothelin and endothelin receptors
-----------------------------------

Endothelins-1, -2, and -3 are peptides of 21 amino acids, produced from different genes in a diverse array of cells, with endothelin-1 (ET-1) -- the only member of the family to be expressed in endothelial cells and vascular smooth muscle cells ([@b78]) -- being a potent paracrine vasoconstrictor that can modulate vasomotor tone, cell proliferation, and vascular remodeling ([@b65]; [@b78]). These peptides exert their biological responses by binding to two types of receptors (ET~A~R and ET~B~R), which are G-protein linked and range in size from 45 kDa to 50 kDa in various cells and tissues, including vascular smooth muscle cells and endothelial cells ([@b108]; [@b112]). Although this is somewhat controversial, a relationship may exist between the expression of endothelin/endothelin receptors and hypertension, with some studies showing overexpression of both ET-1 and its ET~A~R genes in arteries of hypertensive patients ([@b50]; [@b109]) and others finding elevated ET-1 levels in some hypertensive animal models ([@b75]; [@b76]) and in some patients with hypertension ([@b134]). A number of polymorphisms have also been identified within both the ET-1 and ETR genes that have shown associations with either hypertension or elevated pulse pressure ([@b93]; [@b61]). As well, an association has been found between specific ETR polymorphisms and arterial stiffness. In a study by [@b71] 528 untreated hypertensive individuals of European origin (314 men, 214 women) were assessed for aortic stiffness using PWV measurement and association with the ET~A~R −231 A/G and +1363 C/T polymorphisms, the ET~B~R +30 G/A polymorphism, and the ET-1 138 I/D polymorphism. In women, these analyses showed that the age-adjusted PWV was associated with both the ET~A~R −231 A/G polymorphism and the ET~B~R +30 G/A polymorphism, with the −231 G and +30 G alleles being associated in a co-dominant manner with higher PWV, both alleles being significant independent determinants of PWV. In men, no association was seen for any of these polymorphisms and PWV, although the presence of the ET~B~R 30A allele was associated with higher levels of radial artery wall cross-sectional area ([@b71]). The mechanistic basis for such sex-specific association between the ET~A~R polymorphisms and arterial stiffening has yet to be elucidated.

Extracellular matrix gene and matrix metalloproteinase gene polymorphisms
=========================================================================

Matrix homeostasis is also a critical determinant of the mechanical properties of the blood vessel, and the mechanisms whereby matrix proteins are regulated in their accumulation and deposition are therefore likely to play key roles in the process of arterial stiffening ([@b107]). In view of the information pertaining to polymorphism in the genes described above, it is critical to understand the extent to which polymorphism within extracellular matrix genes themselves and genes that encode for the proteins that regulate matrix homeostasis (the matrix metalloproteinases \[MMPs\]) plays a role in relation to the process of arterial stiffening. Evidence is emerging to indicate the contribution of genetic variation to both the composition and accumulation of the arterial extracellular matrix and to the activity of specific MMPs ([@b131]).

Elastin and fibrillin-1
-----------------------

Major determinants of the arterial distensibility of large blood vessels include desmin ([@b68]) and elastin. The latter, a highly insoluble extracellular matrix protein synthesized as a soluble precursor, tropoelastin, by vascular cells (including smooth muscle cells), is the principal component of elastic fibers from the arterial media ([@b129]). Interaction between the elastic fibers and vascular proteoglycans may also influence arterial geometric and elastic properties ([@b43]). Although no studies have yet been carried out to assess the potential association of polymorphisms within the desmin gene and arterial stiffness, a number of polymorphisms have been identified within the elastin gene. One of these, an A-to-G substitution resulting in a serine-to-glycine replacement at amino acid 422 in the elastin protein, has been demonstrated to be associated with carotid artery distensibility, independent of age and blood pressure ([@b48]).

Interestingly, recent genotype-phenotype studies have revealed a potential link between polymorphisms within the fibrillin-1 gene and aortic stiffness and coronary artery disease severity ([@b87]). Fibrillin-1 is the principal constituent of 10-nm microfibrils and functions as a scaffold for the deposition of tropoelastin, thereby participating in both load-bearing and anchoring within the artery. In Marfan syndrome, in which aortic stiffening and elevated pulse pressure are the primary determinant of aortic root dilation ([@b62]), mutations in the fibrillin-1 gene leading to abnormalities in elastic fibers are known to occur ([@b123]). In addition, within the fibrillin-1 gene, a polymorphic (variable) tandem nucleotide repeat (VNTR) sequence, TAAAA, found within intron 28, has been shown to be associated with elevated arterial pulse pressure in men older than 50 years ([@b101]). More recently, this polymorphism has been found to modulate large artery stiffness and pulse pressure within a group of 145 individuals with moderate-severity coronary artery disease ([@b87]). Moreover, individuals heterozygous for fibrillin-1 alleles in which the number of TAAAA repeats was 2 and 3 (2--3 genotype) had stiffer large arteries and higher pulse pressure than other genotypes for this VNTR. Although the precise molecular mechanism linking this intronic polymorphism to large artery stiffening has yet to be elucidated, it may relate to an effect on gene expression or occur via an influence on RNA splicing, as the VNTR is located near the 3′ splicing boundary for exon 28 of the fibrillin-1 gene ([@b98]).

Type I collagen
---------------

Collagen is a primary constituent of extracellular matrix and is abundant in bone, connective tissues, and the arterial wall ([@b6]). There is evidence to suggest an interplay between the levels of elastin and collagen and the mechanical properties of arteries with regard to stiffness ([@b73]; [@b77]). Polymorphism has been shown to exist in the gene encoding for type I collagen, which appears to be associated with arterial stiffness ([@b21]). This polymorphism (2046G/T) is located within the promoter region of the collagen type I-α1 gene (COL1A1) at the first base of a consensus site for the binding of the transcription factor Sp1 and has previously been shown to be associated with reduced bone density and osteoporotic fracture ([@b46]). In a study of 489 Northern Irish individuals (251 men and 238 women) the T allele was associated with a higher aortic PWV, independent of age, sex, and mean arterial pressure ([@b21]). Presumably, this polymorphism alters Sp1 binding and therefore affects transcription rates of the COL1A1 gene, suggesting that altered collagen deposition is directly related to the effects on arterial stiffening.

Matrix metalloproteinase-3 (MMP-3)
----------------------------------

With regard to matrix homeostasis, MMP-3 (stromelysin-1) is likely to be a critical regulator of arterial stiffness, given its wide range of substrates that include most major matrix components within arteries, such as the fibronectins, collagens, gelatins, laminins, elastin, and various proteoglycans ([@b127]). In addition, MMP-3 is capable of activating other MMPs, such as collagenases ([@b89]), matrilysin ([@b56]), and gelatinase B ([@b33]). The level of MMP-3 is regulated primarily by its gene transcription, and its promoter is known to contain sequences that mediate induction by various stimuli, including growth factors and cytokines such as platelet-derived growth factor ([@b64]) and interleukin-12 ([@b90]), and suppression by agents such as dexamethasone ([@b54]). A common polymorphism has been found within the MMP-3 promoter, giving rise to one allele that has a run of six adenosines (6A) and another having a run of five adenosines (5A) at nucleotide position −1171 relative to the transcriptional start site ([@b133]). The ability of this polymorphism to influence expression of MMP-3 via effects on transcription factor binding within the MMP-3 promoter has been demonstrated from cell culture experiments, in which the 5A allele has a higher promoter activity ([@b132]). Moreover, this allele has been associated with acute coronary events ([@b120]) and aortic aneurysms ([@b135]), most likely via an increase in matrix proteolysis. Conversely, the 6A allele has been found to be associated with carotid intimamedia thickening ([@b45]; [@b102]), presumably via a mechanism arising from an increase in matrix accumulation. The relationship between MMP-3 allelic variation and agerelated large artery stiffening appears complex, with a recent study demonstrating that both the 5A/5A and 6A/6A homozygotes are associated with age-related aortic stiffening, as compared with the 5A/6A heterozygotes exhibiting delayed large artery stiffening ([@b88]), thereby implying that either high (5A/5A) or low (6A/6A) MMP-3 activity has an adverse effect on the outcome over time on aortic stiffening. In the situation of high MMP-3 activity, the mechanism underlying the adverse increase in aortic stiffening may arise from the augmented degradation of elastin leading to dilatation of the vessel lumen and a subsequent increase in stiffness as the elastin is replaced with stiffer collagen ([@b96]). Subsequently, adverse effects regarding aneurysmal formation could occur via the thinning of the atherosclerotic vessel wall as collagen is then degraded by high MMP-3 activity, either directly or via its activation of other collagenases ([@b25]). Alternatively, plaque instability could occur via a similar degradation mechanism leading to weakening of the fibrous cap in the advanced atherosclerotic lesion ([@b120]; [@b94]).

Matrix metalloproteinase-9 (MMP-9)
----------------------------------

More recently, a potential involvement of MMP-9 polymorphisms on large artery stiffening has also been reported. MMP-9, otherwise known as gelatinase B, is a 92 kDa type IV collagenase, which has been shown to be highly expressed in the rupture-prone regions of human atherosclerotic plaques ([@b40]). As its name suggests, it is particularly active at degrading gelatins, but its substrate specificity is sufficiently broad to render it capable of also degrading type IV collagen, a primary substituent of the basement membrane that underlies the endothelium and is found enveloping smooth muscle cells ([@b17]). The expression of MMP-9 is controlled in large part at the level of its gene transcription, and it has been shown that factors such as interleukin-1 ([@b55]), platelet-derived growth factor, tumor necrosis factor-α ([@b37]), and epidermal growth factor ([@b66]) can influence the expression of MMP-9 via stimulation of its promoter region. In this regard it has been shown that several *cis*-acting elements in the MMP-9 promoter are critical in the regulation of its transcription, including two AP-1 sites bound by c-*fos* and c-*jun* transcription factors, a PEA3 motif mediating regulation by the ETS transcription factor, and a potential binding site for nuclear factor-κB ([@b55]; [@b47]). Additionally, sites mediating transcriptional repression of the MMP-9 gene have been identified within its promoter ([@b136]). Within this 9-bp sequence a C-to-T polymorphism exists (GCGCA***C/T***GCC), such that repression is minimal when the T substitution (C1562T) occurs, as shown from transient transfection experiments in cultured macrophages ([@b136]). It has also been shown that individuals of the T/T genotype tend to have a higher serum level of MMP-9 than those of either the C/T or C/C genotype ([@b18]); furthermore, in a sample of 374 individuals from France for whom coronary angiographic data were available, there was a significant association between this polymorphism and the severity of coronary atherosclerosis as assessed by the number of coronary arteries that had a stenosis \>50% ([@b136]). Using this criterion, the number of patients with triple-vessel disease was higher in the T/T and C/T genotypes than in the C/C genotypes. Interestingly, this polymorphism has recently been shown to associate with large artery stiffness in a group of individuals with angiographically defined coronary artery disease. Specifically, individuals carrying the T allele (either T/T or C/T genotype) had stiffer large arteries (higher input and characteristic impedance) and higher carotid pulse and systolic blood pressure than individuals with the C/C genotype ([@b86]). Such a relationship remained significant after age, sex, mean arterial pressure, total cholesterol, low-density lipoprotein cholesterol, and triglycerides were considered as covariates.

Moreover, in a subsample of eight aortic tissues from a separate population of cardiac transplant patients, MMP-9 gene expression was found to be fivefold higher in T allele carriers than in individuals with the C/C genotype ([@b86]); within these samples there was a trend towards increased total MMP-9 protein in the T allele carriers, and MMP-9 activity was significantly higher in this group. The mechanism linking increased MMP-9 expression to large artery stiffening could potentially occur via processes involving vascular remodeling events. In this regard it is interesting that in MMP-9-deficient mice, arterial geometrical remodeling within the carotid artery has been observed to be impaired subsequent to flow cessation ([@b39]), an effect most likely exerted through a modulation of collagen metabolism and organization. A relationship between MMP-9 expression and large artery stiffening has also been seen in Marfan syndrome ([@b111]).

Conclusions
===========

It has become increasingly recognized that the stiffening of large arteries, a critical independent predictor of cardiovascular risk, is likely to be profoundly influenced by variation within a diverse array of genes, the proteins for which are involved in the modulation of arterial growth and extracellular matrix properties. An expanding array of genetic polymorphisms has been identified to associate with arterial stiffness. This "candidate gene" approach has yielded significant information about the identity of various genes that are likely to be involved in human arterial stiffening, and for some of these polymorphisms the mechanistic link to this process has been suggested from structure-function studies and supported by studies in appropriate animal models. However, limitations to some of the studies must be acknowledged, particularly where the mechanistic link between the identified polymorphism(s) and the process of arterial stiffening remains to be elucidated or in cases for which specific polymorphisms have not been consistently associated with arterial stiffness between different population groups. In this regard, the use of complementary approaches such as gene array profiling between individuals with increased arterial stiffening as compared with individuals with more distensible arteries has the potential to discern genes in which polymorphisms result in perturbations in protein expression, rather than direct effects on protein function. The applicability of such an approach has already been shown in a study in which a diverse set of genes, including those involved in cellular signaling and the mechanical regulation of vascular structure, were seen to be differentially expressed in aortas with increased stiffness ([@b34]). The situation is likely to be even more complex when the influence of linkage disequilibrium and the combination of various polymorphisms, or haplotypes, is additionally considered. This has been shown by studies indicating that when combinatorial arrays of specific polymorphisms, either from the same gene or between different genes, are used to evaluate relationships to arterial stiffening, associations exist that either were not evident or were less apparent when considering one polymorphism alone ([@b5]; [@b91]). Clearly, future research in which there is an integration of genetic, molecular, biochemical, clinical, and epidemiological studies (as similarly advocated by [@b116]) to elucidate the genetic and environmental factors that interact to cause human hypertension should contribute significantly to a greater understanding of the heritable factors that act to modulate arterial stiffness. Ultimately, the clarification of these genetic influences will allow for the targeting of key factors for therapeutic benefit, particularly in individuals with either increased or premature arterial stiffening.
